RxDoctor Payments Data

Thomas Biggs, DO

Ophthalmology · Clarkston, MINPI 1932188224

Payments from drug & device makers

$4,558in general payments, 2019–2025

Across 124 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Musculoskeletal Transplant Foundation Inc.$246
  • Carl Zeiss Meditec USA, Inc.$209
  • Rxsight Inc$201
  • Ocular Therapeutix, Inc.$188
  • Sight Sciences, Inc.$150
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$4,52899%
  • Education$301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,558 in reported general payments places this provider in the 80th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$236,659
Medicare patients
602
Services billed
2,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost102$50,374
RestasisCyclosporine28$38,995
Timolol Maleate204$24,443
Cyclosporine42$24,383
Bromfenac Sodium66$17,836
Bimatoprost95$12,643
Prednisolone Acetate376$12,573
ProlensaBromfenac Sodium31$10,720
CombiganBrimonidine Tartrate/Timolol21$8,702
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol38$7,215
Latanoprost282$6,489
RocklatanNetarsudil Mesylat/Latanoprost13$6,054
Brimonidine Tartrate54$4,467
Ofloxacin264$2,924
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat81$2,191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$126$98,070151 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$84$10,72031 claims
Aerie Pharmaceuticals, Inc.Rocklatan$13$6,05413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →